Abstract 1503P
Background
Spirituality is important in cancer care. Few studies have assessed the spiritual needs (SN) of cancer patients. The purpose of this study was to assess the SN of patients undergoing curative or palliative cancer treatments, and to evaluate the relationship between SN and their health-related quality of life (QOL).
Methods
We conducted a cross-sectional study using a brief questionnaire on the healthcare team's approach to spirituality, the Duke University Religion Index (DUREL), the Functional Assessment of Chronic Illness Therapy Spiritual Well Being Version 4 (FACIT-SP), and the Spiritual Needs Assessment for Patients (SNAP) in outpatient adults with solid tumors undergoing curative-intent or palliative cancer treatments. Informed consent was obtained from all patients.
Results
From March to October/2022, 150 patients were included: 75 receiving curative-intent treatment and 75, palliative. Patients who wanted a spirituality approach by the healthcare team had higher total SN and psychosocial, spiritual, and religious scores than patients who did not want it (p < 0.0001), but lower QOL scores (FACIT-G p = 0.001 and FACIT-SP p = 0.004). SN or QOL did not differ according to treatment intention (p = 0,444 and p = 0,159 respectively), age (r = 0,059), education level (p = 0,999), sex (p = 0,186), or marital status (p = 0,528). There was a predominant weak correlation between SN and QOL (r < 0,4); a moderate negative relationship between emotional well-being and spiritual domain needs (r = -0,416); a weak correlation between SN and the three dimensions of DUREL (r < 0,4); a moderate positive relationship (0,461 < r < 0,616) between faith subscale of spiritual well-being and the three dimensions of DUREL; and also, a moderate positive relationship (r = 0,410) between spiritual well-being and intrinsic religiosity.
Conclusions
In our study, patients who wanted a spiritual approach from the healthcare team had higher SN and lower QOL. SN were not related to cancer treatment intentions or the patient religiosity. Assessment of spirituality may improve cancer care, and further studies could evaluate screening and interventions in this area.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10